355 / 1631
Conclusions
• Large numbers of well conducted RCT supporting CMT
• Recent FDG-PET data inform patient specific discussions
about risk of relapse (increased over chemo alone)
versus late toxicity (potentially increased with CMT but
patient specific)
• Response adapted treatment using FDG PET
-
Ongoing
challenges to implement in routine clinical practice with
QA measures required to meet Deauville criteria
• Patient specific risk models are being developed
alongside further biomarkers eg TMTV